A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Decitabine (Primary) ; Ipilimumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 21 Aug 2024 Planned End Date changed from 1 Jul 2024 to 19 Aug 2025.
- 04 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 04 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.